Evaluation of miR-155 Expression in Peripheral Blood Samples of COPD Patients

Abstract

Introduction: Chronic obstructive pulmonary disease (COPD) is a progressive, irreversible chronic inflammatory disorder characterized by the increased recruitment of monocytes, lymphocytes, and neutrophils. Beyond the lungs, COPD is associated with systemic inflammation, skeletal complications such as osteoporosis, and poor oral and periodontal health, all of which are clinically relevant in oral and maxillofacial practice. This study aims to investigate the changes in miR-155 expression in the peripheral blood of COPD patients compared to healthy individuals. Materials and Methods: In this descriptive-cross-sectional study, 35 peripheral blood samples from COPD patients and 35 peripheral blood samples from healthy individuals were collected. RNA extraction was immediately performed, followed by Real-Time PCR to assess the changes in miR-155 expression. Results: The miR-155 biomarker was positive in the peripheral blood of 25 out of 35 patients. In the group of healthy individuals, this biomarker was positive in 6 out of 35 cases. Statistical analysis of the positivity rate of this biomarker between the patient group and the healthy group showed a significant difference. Based on the findings of this study, the expression of miR-155 is increased in COPD patients compared to healthy individuals. Conclusion: The miR-155 biomarker could potentially play an important role in the identification and diagnosis of COPD in patients. Given the growing evidence that COPD-related systemic and oral inflammation adversely affects periodontal status, jawbone health, and perioperative risk in oral and maxillofacial surgery, circulating miR-155 may also serve as a useful adjunct biomarker for risk stratification and multidisciplinary management of COPD patients in craniomaxillofacial settings. However, further studies are recommended. Keywords: COPD; miRNA; Real-Time PCR; miR-155.